Stock Talk

In a Q&A posted at Market Playground, AlphaNorth Asset Management Chief Investment Officer Steven Palmer tells The Life Sciences Report's George Mack that when it comes to pharma and biotech investments, "it is all about risk versus reward." For that reason, Palmer says he generally errs on the side of investing in established, later-stage companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.